Berliner Boersenzeitung - Canadian fund drops bid for Spanish pharma firm Grifols

EUR -
AED 3.885561
AFN 71.400618
ALL 98.79328
AMD 414.292695
ANG 1.907403
AOA 963.698942
ARS 1066.336254
AUD 1.628103
AWG 1.904163
AZN 1.795023
BAM 1.966261
BBD 2.136919
BDT 126.474081
BGN 1.955959
BHD 0.398799
BIF 3063.586381
BMD 1.057868
BND 1.421328
BOB 7.313739
BRL 6.226927
BSD 1.058406
BTN 89.364294
BWP 14.45872
BYN 3.463545
BYR 20734.21722
BZD 2.133299
CAD 1.483819
CDF 3036.081522
CHF 0.93176
CLF 0.037478
CLP 1034.140602
CNY 7.665949
CNH 7.663785
COP 4650.653186
CRC 540.581189
CUC 1.057868
CUP 28.033508
CVE 110.853206
CZK 25.263985
DJF 188.00465
DKK 7.45924
DOP 63.800041
DZD 141.14823
EGP 52.544905
ERN 15.868023
ETB 133.775068
FJD 2.398346
FKP 0.834993
GBP 0.83437
GEL 2.887538
GGP 0.834993
GHS 16.457169
GIP 0.834993
GMD 75.108704
GNF 9120.611028
GTQ 8.165443
GYD 221.422813
HKD 8.230934
HNL 26.768417
HRK 7.546048
HTG 138.809829
HUF 412.972726
IDR 16784.401733
ILS 3.868598
IMP 0.834993
INR 89.313751
IQD 1386.489712
IRR 44523.025916
ISK 144.726771
JEP 0.834993
JMD 167.179453
JOD 0.750344
JPY 159.428672
KES 137.046879
KGS 91.83513
KHR 4258.596826
KMF 496.087495
KPW 952.081002
KRW 1471.664088
KWD 0.325178
KYD 0.88198
KZT 531.935107
LAK 23239.09082
LBP 94776.202446
LKR 307.98148
LRD 189.445228
LSL 19.202464
LTL 3.12361
LVL 0.639894
LYD 5.178552
MAD 10.604621
MDL 19.383854
MGA 4952.230549
MKD 61.534897
MMK 3435.914732
MNT 3594.636173
MOP 8.481706
MRU 42.073853
MUR 49.423082
MVR 16.343633
MWK 1835.220639
MXN 21.778455
MYR 4.699583
MZN 67.594496
NAD 19.202464
NGN 1787.828721
NIO 38.947213
NOK 11.691316
NPR 142.978315
NZD 1.791084
OMR 0.407285
PAB 1.058406
PEN 3.9903
PGK 4.267604
PHP 62.087871
PKR 294.091951
PLN 4.304395
PYG 8273.015308
QAR 3.857532
RON 4.978005
RSD 117.030899
RUB 119.70066
RWF 1458.338186
SAR 3.973993
SBD 8.876139
SCR 14.379774
SDG 636.299149
SEK 11.528351
SGD 1.416755
SHP 0.834993
SLE 24.015219
SLL 22182.972765
SOS 604.904004
SRD 37.438486
STD 21895.736441
SVC 9.261361
SYP 2657.925503
SZL 19.199329
THB 36.505443
TJS 11.350923
TMT 3.713117
TND 3.324903
TOP 2.477632
TRY 36.659157
TTD 7.184291
TWD 34.353179
TZS 2798.7078
UAH 44.065804
UGX 3905.687309
USD 1.057868
UYU 45.36026
UZS 13598.02485
VES 49.396389
VND 26853.984905
VUV 125.592242
WST 2.953135
XAF 659.456185
XAG 0.035212
XAU 0.000401
XCD 2.858941
XDR 0.809588
XOF 659.465585
XPF 119.331742
YER 264.38771
ZAR 19.209908
ZMK 9522.027644
ZMW 28.8669
ZWL 340.633137
  • RBGPF

    1.0000

    62

    +1.61%

  • RYCEF

    0.1100

    6.91

    +1.59%

  • SCS

    -0.0700

    13.47

    -0.52%

  • CMSC

    -0.0500

    24.52

    -0.2%

  • GSK

    0.3100

    34.33

    +0.9%

  • RIO

    0.2900

    62.32

    +0.47%

  • CMSD

    -0.0700

    24.36

    -0.29%

  • RELX

    0.2400

    47.05

    +0.51%

  • NGG

    0.5000

    63.33

    +0.79%

  • BTI

    0.2300

    37.94

    +0.61%

  • VOD

    0.1100

    8.97

    +1.23%

  • BP

    0.1700

    29.13

    +0.58%

  • BCC

    -2.0100

    146.4

    -1.37%

  • AZN

    0.8400

    67.2

    +1.25%

  • BCE

    0.3900

    27.02

    +1.44%

  • JRI

    0.1700

    13.41

    +1.27%

Canadian fund drops bid for Spanish pharma firm Grifols
Canadian fund drops bid for Spanish pharma firm Grifols / Photo: Josep LAGO - AFP

Canadian fund drops bid for Spanish pharma firm Grifols

Canadian investment fund Brookfield said Wednesday it has dropped its bid for Spanish pharmaceutical firm Grifols following disagreement over its valuation.

Text size:

Brookfield and the Grifols family, which owns about a third of the Barcelona-based company that makes medicine derived from blood plasma, have since July been in talks to take it private.

Earlier this month Brookfield made a 6.45-billion-euro bid for Grifols, offering a tentative non-binding price of 10.50 euros ($11) per share.

Grifols swiftly rejected the bid, saying it "significantly underestimated the fundamental prospects and long-term potential" of the company.

In a statement sent to Spanish stock market regulator CNMV, Brookfield said it was "not in a position to continue with a potential offer" for Grifols.

Grifols said its board agreed that "it is not feasible that the transaction goes ahead" and remains focused on "improving the company's long-term value".

Its share price plunged in January after US hedge fund Gotham City released a research note accusing the company of "manipulating" its reported debt and operational results to "artificially reduce" its debt ratio, and therefore its financing costs.

Grifols has repeatedly denied the allegations.

Gotham City is a prominent "short-seller" hedge fund that borrows stock in a company and sells it, hoping to buy it back cheaper to return it to the lender and pocket the difference.

Grifols traces its history back to 1909, first as a blood analysis and transfusion laboratory before specialising in products derived from blood plasma.

It is present in more than 30 countries including Australia, the United States and Japan. It posted revenue of 6.6 billion euros in 2023, a 10.9 percent increase over the previous year.

(T.Burkhard--BBZ)